Gilead Sciences (GILD) fundamentals: P/E, valuation, undervalued?
Gilead Sciences · Health Care · ref. ETF XLV · price $147.92
In short — Gilead Sciences trades at —× earnings (P/E), 14.9× forward, with a net margin of -10.6 % and revenue growth of +10 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Gilead Sciences stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$147.92+24.8% over range
Oct 14, 25low $117.85 · high $155.8Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
70% recommend buying · 10 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
14.9
Forward P/E
—
PEG
15.5
Price/book (P/B)
$183.4B
Market cap
-2.61
EPS
Profitability & growth
-10.6 %
Net margin
+10 %
Revenue growth
—
Earnings growth
$26.2B
Total debt
Gilead Sciences income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $27.3B | $4.6B | 16.8 % |
| 2023 | $27.1B | $5.7B | 20.9 % |
| 2024 | $28.8B | $480M | 1.7 % |
| 2025 | $29.4B | $8.5B | 28.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Gilead Sciences's P/E and is the stock undervalued? What's a good P/E?
Gilead Sciences's P/E is — (forward 14.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Gilead Sciences profitable?
Gilead Sciences has a net margin of -10.6 % (EPS -2.61). The company is not (yet) profitable.
Is GILD stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Gilead Sciences? The JPI assistant answers using our backtest data.
Keep exploring Gilead Sciences